Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart rhythm registry aims to uncover hidden risks in AF patients

NCT ID NCT07437456

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This registry will follow 3,500 adults with atrial fibrillation who have a low risk of stroke. Researchers will track complications like stroke and hospitalizations over time to see how patients are managed in everyday medical practice. The goal is to better understand outcomes and treatments in this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Anonymized male and female patients aged 18 to 64 years suffering from atrial fibrillation confirmed by a specialist, with a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Retrospective Part The retrospective part will include patients who attended a physician consultation for atrial fibrillation three years ago and who met the inclusion criteria at that time. Inclusion criteria for the retrospective part: * Male or female patients aged 18 to 64 years at the time of data registration; * Presence of a specialist-confirmed diagnosis of atrial fibrillation; * CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women. Non-inclusion criteria for the retrospective part: * Age under 18 years; * Age over 64 years; * CHA₂DS₂-VASc score greater than 2 for men and greater than 3 for women; * Inability to undergo screening examination and follow-up; * Organ or tissue transplantation less than 5 years prior to study enrollment; * Open heart surgery (coronary artery bypass grafting, valve replacement, reconstructive aortic surgery) within 6 months prior to study enrollment; * Established diagnosis of dementia of any severity and/or established diagnosis of moderate or severe encephalopathy, as well as other conditions precluding independent regular medication intake. Prospective Part Inclusion criteria for the prospective part: * Male or female patients aged 18 to 64 years at the time of data registration; * Presence of a specialist-confirmed diagnosis of atrial fibrillation; * CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening. Non-inclusion criteria for the prospective part: * Age under 18 years; * Age over 64 years; * CHA₂DS₂-VASc score greater than 2 for men and greater than 3 for women; * Inability to undergo screening examination and follow-up; * Organ or tissue transplantation less than 5 years prior to study enrollment; * Open heart surgery (coronary artery bypass grafting, valve replacement, reconstructive aortic surgery) within 6 months prior to study enrollment; * Established diagnosis of dementia of any severity and/or established diagnosis of moderate or severe encephalopathy, as well as other conditions precluding independent regular medication intake. Exclusion criteria: * Patient withdrawal of consent for further participation in the study; * Identification of factors precluding further patient participation in the study (at the physician's discretion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eurasian Association of Therapists

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.